- Home
- ROMA vs MIST Comparison
ROMA vs MIST Comparison
Compare ROMA & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROMA | MIST |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.7M | 176.3M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | ROMA | MIST |
|---|---|---|
| Price | $2.12 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 6.4K | ★ 10.1M |
| Earning Date | 12-26-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,640,101.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.60 | N/A |
| 52 Week Low | $0.58 | $0.63 |
| 52 Week High | $4.66 | $3.06 |
Technical Indicators
Market Signals| Indicator | ROMA | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 42.75 |
| Support Level | $1.83 | $1.90 |
| Resistance Level | $2.59 | $2.22 |
| Average True Range (ATR) | 0.28 | 0.33 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 49.14 | 33.20 |
Price Performance
Historical ComparisonAbout ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).